Case studies of the utility of serum carbohydrate-deficient transferrin (%CDT) in the clinical management of alcoholics.
A laboratory test that measures the percentage of carbohydrate-deficient transferrin (%CDT) has been approved by the FDA for the detection of heavy alcohol use. This biomarker has unique properties and has proven to be a useful tool in multiple clinical settings. It can be used for screening and monitoring purposes in patients with suspected or known alcohol use disorders. We review the use of this test in the management of 5 patients seen in the mental health and substance abuse clinics at a Department of Veterans Affairs Medical Center.